Vanguards of Healthcare: Senseonics Extends CGM Life to a Year
“We have the best-in-class accuracy, especially at the low end for predicting hypoglycemia, which is really important because of that light generation,” says Senseonics CEO Tim Goodnow, explaining the company’s implantable Eversense continuous glucose monitor (CGM) to Bloomberg Intelligence. Goodnow...
360° PERSPECTIVE
Verified viewpoints, counter-arguments & evidence
Related Stories
Oil Futures Pick Up as Middle East Risks Remain
30 minutes ago
Northrop Won’t Contest Boeing’s $20 Billion F/A-XX Navy Contract
1 hour ago
After Foie Gras, NYC Council Takes Aim at Boiling Lobsters Alive
1 hour ago
U.S. Diesel Prices to Continue to Fall in Relief for Consumers, U.S. Energy Secretary Says
2 hours ago
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].


Comment
0Upholding journalistic discourse. No registration required.
No comments yet. Share your perspective!